Dr John Melki – CEO and Director – Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.
Copyright 2023 – Finance News Network
14 Oct 2024 - Hiremii Limited (ASX:HMI) Managing Director and CEO Andrew Hornby discusses revolutionising recruitment through AI integration, touching on the company's revenue growth, international expansion, and opportunities in the resources and energy sectors.
16 Dec 2019 - Sienna Cancer Diagnostics Limited (ASX:SDX) Managing Director and CEO Carl Stubbings talks about the company's capital raising and co-development of tests using its SIEN-NET liquid biopsies platform technology.
27 May 2022 - TerraCom Limited (ASX:TER) Executive Chairman Craig Ransley discusses drivers behind the company's performance and share price over the previous year.
16 Sep 2024 - Quantum Brilliance CEO Mark Luo discusses how his company is pioneering quantum computing with synthetic diamonds, offering a miniaturised and energy-efficient alternative. He highlights the company's rapid growth since its spin-out from the Australian National University, its unique approach to quantum technology and the enormous commercial potential of quantum at the edge.
10 Jul 2023 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent news, including excellent sensitivity and specificity results for the company's SubB2M breast cancer test.
26 Mar 2020 - Cashwerkz Limited (ASX:CWZ) Executive Chairman John Nantes talks about the company's 1H20 results, new partners to the platform, outlook for the second half and impact of COVID-19.
30 Sep 2019 - Symposium, Managing Director, Kerry Stevenson talks about the importance of gold in a diversified portfolio, its successful performance over the past 12 months and all that’s on offer at this year’s event, 24-26 October, Sydney Sofitel Wentworth.
17 Nov 2022 - Genetic Signatures Limited (ASX:GSS) CEO and Director Dr John Melki discusses the company's technology, business model, 2022 highlights and outlook.